Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-α and survivin

Breast Cancer Research

Volumn 12, Issue 3, 2010, Pages

  Vanderlaag, Kathryn E ^a   Hudak, Susan ^a   Bald, Laura ^a   Fayadat Dilman, Laurence ^a   Sathe, Manjiri ^a   Grein, Jeff ^a   Janatpour, Mary J ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTERIOR GRADIENT 2; BROXURIDINE; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LIPOCORTIN 5; PROTEIN; SMALL INTERFERING RNA; SURVIVIN; TAMOXIFEN; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; ANTIESTROGEN; BIRC5 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; DRUG DERIVATIVE; ESR1 PROTEIN, HUMAN; ESTRADIOL; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; EVALUATION; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; ONCOGENE C MYC; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BREAST TUMOR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENETICS; IMMUNIZATION; LEWIS RAT; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYCLIN D1; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROTUBULE-ASSOCIATED PROTEINS; PROTEINS; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TAMOXIFEN;

EID: 78149491523     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2586     Document Type: Article

References (47)

1. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. , http://seer.cancer.gov/csr/1975_2005/
2. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002, 76:27-36. 10.1023/A:1020299707510, 12408373.
3. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992, 7:1587-94.
4. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-24.
5. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-7.
6. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002, 1:226-31.
7. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994, 14:2066-76. 358567, 8114738.
8. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-21. 10.1038/35082500, 11429595.
9. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-58. 10.1677/erc.1.00776, 15613444.
10. Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998, 251:111-6. 10.1006/bbrc.1998.9440, 9790916.
11. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005, 65:3796-805. 10.1158/0008-5472.CAN-04-3823, 15867376.
12. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006, 13:617-28. 10.1677/erc.1.01165, 16728587.
13. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9:R37. 10.1186/bcr1732, 1929101, 17555561.
14. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005, 43:249-59. 10.1002/gcc.20188, 15834940.
15. Pohler E, Craig AL, Cotton J, Lawrie L, Dillon JF, Ross P, Kernohan N, Hupp TR. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 2004, 3:534-547. 10.1074/mcp.M300089-MCP200, 14967811.
16. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005, 205:359-76. 10.1002/path.1676, 15532095.
17. Shen D, Chang HR, Chen Z, He J, Lonsberry V, Elshimali Y, Chia D, Seligson D, Goodglick L, Nelson SF, Gornbein JA. Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun 2005, 326:218-27. 10.1016/j.bbrc.2004.10.214, 15567174.
18. Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G. Expression of AGR2 in non small cell lung cancer. Histol Histopathol 2007, 22:703-8.
19. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006, 12:1728-34. 10.1158/1078-0432.CCR-05-2057, 16551856.
20. Kovalev LI, Shishkin SS, Khasigov PZ, Dzeranov NK, Kazachenko AV, Kovaleva MA, Toropygin I, Eremina LS, Grachev SV. [New approaches to molecular diagnosis of prostatic cancer]. Urologiia 2006, 16-9.
21. Innes HE, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006, 94:1057-65. 10.1038/sj.bjc.6603065, 2361240, 16598187.
22. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007, 10:293-300. 10.1038/sj.pcan.4500960, 17457305.
23. Zhu H, Lam DC, Han KC, Tin VP, Suen WS, Wang E, Lam WK, Cai WW, Chung LP, Wong MP. High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett 2007, 245:303-14. 10.1016/j.canlet.2006.01.020, 16517066.
24. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008, 68:7811-8. 10.1158/0008-5472.CAN-08-1320, 18829536.
25. Wu ZS, Wu Q, Ding XD, Wang HQ, Shen YX, Fang SY. [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance. Zhonghua Bing Li Xue Za Zhi 2008, 37:109-13.
26. Zweitzig DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM, Moran E. Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol Cell Biochem 2007, 306:255-60. 10.1007/s11010-007-9562-y, 17694278.
27. Kamby C, Rose C, Iversen H, Holm NV, Andersen KW, Thorpe SM. [The pattern of metastases in breast cancer and the relation to estrogen receptor status]. Ugeskr Laeger 1986, 148:2546-8.
28. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008, 68:492-7. 10.1158/0008-5472.CAN-07-2930, 18199544.
29. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005, 4:131-9.
30. Frankfurt OS. Detection of apoptosis in leukemic and breast cancer cells with monoclonal antibody to single-stranded DNA. Anticancer Res 1994, 14:1861-9.
31. Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006, 11:473-85. 10.1007/s10495-006-5881-9, 16532373.
32. Gergely P, Grossman C, Niland B, Puskas F, Neupane H, Allam F, Banki K, Phillips PE, Perl A. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:175-90. 10.1002/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H, 11817589.
33. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003, 10:179-86. 10.1677/erc.0.0100179, 12790780.
34. Kharat I, Saatcioglu F. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the ligande estrogen receptor: cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 1996, 271:10533-7. 10.1074/jbc.271.18.10533, 8631852.
35. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-12. 10.1038/nrc721, 12635173.
36. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23:7979-89. 10.1038/sj.onc.1208076, 15489915.
37. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006, 341:73-81. 10.1016/j.bbrc.2005.12.164, 16412380.
38. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2008, 115:57-67. 10.1007/s10549-008-0058-6, 18493848.
39. Park SW, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, Barczak AJ, Killeen N, Erle DJ. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 2009, 106:6950-5. 10.1073/pnas.0808722106, 2678445, 19359471.
40. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 1998, 22:66-71. 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5, 9591636.
41. Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006, 66:9895-902. 10.1158/0008-5472.CAN-05-4589, 17047051.
42. Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, Barker J, Bicknell R. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 2003, 278:47079-88. 10.1074/jbc.M308124200, 12963716.
43. Jamerson MH, Johnson MD, Dickson RB. Of mice and Myc: c-Myc and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2004, 9:27-37. 10.1023/B:JOMG.0000023586.69263.0b, 15082916.
44. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008, 19:1379-86. 10.1093/annonc/mdn291, 18487549.
45. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5. 10.1158/1078-0432.CCR-08-0746, 18698017.
46. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996, 56:2321-30.
47. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005, 12:721-47. 10.1677/erc.1.00857, 16322319.